C. Bulaï Livideanu

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

Olivier Lortholary, Marie‐Olivia Chandesris, C. Bulaï Livideanu et al. · The Lancet · 2017 · 119 citations · Full text

Medicine, Mast Cell Disorder, Allergy +1

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Erinn Soucié, Katia Hanssens, Thomas Mercher et al. · Blood · 2012 · 96 citations · Full text

ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases

Gandhi Damaj, Magalie Joris, Marie‐Olivia Chandesris et al. · PLoS ONE · 2014 · 77 citations · Full text

Hematological Malignancy, Autoimmune Disease, Scleroderma +13

GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis

M. Larsabal, S. Ly, É. Sbidian et al. · British Journal of Dermatology · 2018 · 76 citations

Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS

Richard Lemal, Guillemette Fouquet, Louis Terriou et al. · The Journal of Allergy and Clinical Immunology In Practice · 2019 · 71 citations · Full text

Clinical Allergy, Allergy Medicine, Mast Cell Disorder +5